ANAB Financials

Income Statement
MetricQ1 2027Q4 2025Q3 2025Q1 2026Q2 2025
Revenue
30.3M
-72.0%
108.2M
+41.8%
76.3M
+0.0%
76.3M
+242.8%
22.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
30.3M
-72.0%
108.2M
+41.8%
76.3M
+0.0%
76.3M
+242.8%
22.3M
Operating Expenses
10.4M
-74.9%
41.3M
-0.6%
41.6M
+4471.4%
-952000
-102.0%
48.4M
R&D
-1267000
-105.0%
25.6M
-18.6%
31.4M
+1643.3%
-2035000
-105.4%
37.8M
SG&A
11.6M
-26.3%
15.8M
+54.7%
10.2M
+842.7%
1.1M
-89.8%
10.6M
Operating Income
19.9M
-70.2%
66.9M
+92.8%
34.7M
-55.1%
77.3M
+395.3%
-26170000
EBITDA
19.9M
-70.3%
67.0M
+92.4%
34.8M
-54.9%
77.3M
+396.9%
-26028000
Net Income
3.9M
-92.2%
49.6M
+228.3%
15.1M
+0.0%
15.1M
+139.1%
-38630000
EPS (Basic)
$0.13
-92.7%
$1.79
+231.5%
$0.54
+0.0%
$0.54
+140.3%
$-1.34
EPS (Diluted)
$0.11
-94.1%
$1.87
+259.6%
$0.52
+0.0%
$0.52
+138.8%
$-1.34
Shares (Diluted)
35.1M
+32.0%
26.6M
-8.5%
29.0M
+0.0%
29.0M
+0.7%
28.8M
AnaptysBio (ANAB) — Financials